South Africa Faces HIV Funding Cuts by US, Amid Lenacapavir Rollout

By VL Bandi - Echos News Editorial Desk
Published: June 20, 2026

South Africa, home to the world’s largest HIV epidemic, is at a critical crossroads. The United States has announced the phase‑out of PEPFAR (President’s Emergency Plan for AIDS Relief) funding, a program that has supported millions of South Africans living with HIV/AIDS for over two decades. At the same time, South Africa is rolling out Lenacapavir, a revolutionary twice‑yearly injection that offers near‑perfect protection against HIV infection. The convergence of these two developments raises urgent questions about the future of the country’s HIV response.

PEPFAR Withdrawal and Its Impact

Since its launch in 2003, PEPFAR has been a cornerstone of global HIV/AIDS relief, channeling billions of dollars into prevention, testing, and treatment programs. In South Africa, annual support once exceeded $450 million. However, funding has been reduced dramatically: from $456 million in 2024 to $213 million in 2025, and only $25 million allocated in 2026. The U.S. government cites political disputes, including allegations of discrimination against white Afrikaners, as the reason for withdrawal.

The implications are profound. South Africa has 7.8–8 million people living with HIV, the highest number globally. PEPFAR previously covered about 20% of the national HIV program budget. Without this support, outreach, testing, and prevention efforts risk being scaled back, potentially reversing two decades of progress. Experts warn that the loss of funding could lead to treatment interruptions, rising infection rates, and setbacks in achieving UNAIDS targets.

Shop Amazon Deals

Lenacapavir: A Game‑Changing Innovation

Amid this funding crisis, South Africa has begun rolling out Lenacapavir, a long‑acting pre‑exposure prophylaxis (PrEP) injection. Administered once every six months, Lenacapavir has shown nearly 100% effectiveness in preventing HIV infection among HIV‑negative individuals. Unlike daily pills, the injection is discreet, reduces stigma, and improves adherence, especially among young women and high‑risk groups.

In 2026, Lenacapavir became available at 360 government clinics across six provinces, including Gauteng, KwaZulu‑Natal, and the Western Cape. Provinces such as Limpopo and the Free State are scheduled to receive supplies in 2027, once generics are approved. South Africa has already received over 95,000 doses this year, with another 57,600 expected mid‑June, funded by the Global Fund. This rollout represents a significant step toward innovation and self‑reliance in HIV prevention.

Global Adoption Beyond South Africa

South Africa is not alone in embracing Lenacapavir. Other countries, including Kenya, Uganda, and the United States, have begun pilot programs or limited rollouts. In Kenya, Lenacapavir is being introduced for adolescent girls and young women, while Uganda is targeting high‑risk populations such as sex workers. In the United States, the drug has been approved for prevention trials among men who have sex with men and people who inject drugs. This global uptake underscores Lenacapavir’s potential to reshape HIV prevention strategies worldwide, offering hope that long‑acting PrEP could become a cornerstone of global HIV elimination efforts.

Shop Amazon Deals

Outcome Hinges on Speed and Scale

The future of South Africa’s HIV response depends on how quickly and widely Lenacapavir can be scaled. As analysts note: “The outcome hinges on speed and scale. If South Africa can rapidly expand Lenacapavir access while closing the funding gap left by PEPFAR, the country could transform its HIV response into a self‑sustaining model. But if rollout stalls and funding gaps persist, progress risks being reversed, especially among vulnerable groups.”

In the short term, the loss of PEPFAR funding threatens to slow testing and outreach, increasing the risk of new infections. In the medium term, Lenacapavir offers a powerful shield against HIV, but supply limitations and cost barriers remain. In the long term, if South Africa can expand access to 1–2 million HIV‑negative individuals annually, modelling suggests the country could end AIDS as a public health crisis by 2043. This would mark a historic achievement, but only if political will and financial commitment align with scientific innovation.

Related Coverage

• South Africa at the Frontline of HIV

Balancing Risks and Opportunities

South Africa’s challenge is twofold: to secure alternative funding sources and to accelerate Lenacapavir rollout. Partnerships with pharmaceutical companies and the introduction of generics in 2027 are expected to lower costs, making the injection more accessible. The Global Fund and domestic financing will play critical roles in bridging the gap left by PEPFAR. Regional cooperation with countries like Kenya and Uganda could also strengthen supply chains and knowledge sharing.

Ultimately, South Africa’s HIV response is entering a new era. The withdrawal of U.S. support is a setback, but the arrival of Lenacapavir represents a historic opportunity. Whether the country can seize this moment depends on speed, scale, and the ability to deliver innovation to those who need it most. The stakes are high: millions of lives, decades of progress, and the possibility of ending AIDS as a public health crisis within a generation.

© 2026 Echos News ZA. All rights reserved.

Disclaimer:

This article is published by Echos News ZA for informational and editorial purposes. All content is based on verified sources and independent editorial judgment. Echos News ZA does not endorse or oppose any political party, public figure, or organization. Readers are encouraged to consult original reports and official releases for complete context.

Copyright for images, videos, and external materials belongs to their original creators. Echos News ZA does not host, store, or upload third‑party content, and any use of such materials is under fair use, commentary, or with proper attribution where applicable.

Our coverage complies with Google AdSense policies on factual reporting, neutrality, and non‑sensational content.

⬅ Return to Home